eplivanserin planned trade name ciltyri experimental drug treatment insomnia developed sanofi sanofi aventis announced december withdrawing application approval eplivanserin us food drug administration european medicines eplivanserin inverse agonist serotonin receptor subtype contrast older sedating drugs acting receptors eg mirtazapine clozapine risperidone eplivanserin practically affinity dopamine histamine adrenergic placebo controlled phase ii clinical trial subjects eplivanserin reduced sleep latency minutes versus minutes condensation give chalcone intermediate also enone ie cdma acetone oxime reacted together give dimethylaminoacetoxime dma acetoxime convergent synthesis gives product mixture isomers sedativerelated article stub help wikipedia expanding ithttpsenwikipediaorgwikieplivanserin